The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil

I Sáenz de TejadaJavier AnguloPedro CuevasAranzazu Fernández-MartínezIgnacio MoncadaA AllonaEva M Peñas- LLedóHG KörschenUlrich NiewöhnerHelmut Haning2026-03-222026-03-22200110.1038/sj.ijir.3900726https://doi.org/10.1038/sj.ijir.3900726https://andeanlibrary.org/handle/123456789/44064Citaciones: 231enVardenafilcGMP-specific phosphodiesterase type 5SildenafilIn vivoSodium nitroprussidePhosphodiesterase 3PharmacologyNitric oxideIC50PotencyThe phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafilarticle